Fast Five Quiz: Management of Inherited Retinal Diseases

Donny W. Suh, MD, MBA

Disclosures

April 27, 2022

RNA gene therapy targeting recurrent mutations in USH2A may be a future promising treatment option for patients with retinitis pigmentosa. Phase 1/2 trials to evaluate the safety and tolerability of therapy were completed in 2021 and demonstrated improvement in best corrected visual acuity, static perimetry, and optical coherence tomography (OCT) retinal imaging; no serious adverse effects were reported. Phase 2/3 trials are planned to follow.

Early studies have suggested that stem cell–based therapies may be beneficial in IRD. However, there are no proven effective cell-based treatments for retinal diseases.

Learn more about inherited retinal diseases.

Comments

3090D553-9492-4563-8681-AD288FA52ACE
Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.

processing....